Chapel Hill-based biopharmaceutical company, Tenax Therapeutics, Inc., has announced the development and commercialization of pharmaceutical products that include imatinib for the treatment of pulmonary arterial hypertension. After completing phase II clinical trials, Tenax Therapeutics is set to market TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) for patients with heart failure and associated pulmonary hypertension. Furthermore, TNX-201 (imatinib), a tyrosine kinase inhibitor, is in development for the treatment of chronic myeloid leukemia. Founded in 1967 and previously known as Oxygen Biotherapeutics, Inc., Tenax Therapeutics, Inc. changed its name in September 2014.
Tenax Therapeutics, Inc.'s ticker is TENX
The company's shares trade on the NASDAQ stock exchange
They are based in Morrisville, North Carolina
There are 1-10 employees working at Tenax Therapeutics, Inc.
It is http://www.tenaxthera.com/
Tenax Therapeutics, Inc. is in the Healthcare sector
Tenax Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Tenax Therapeutics, Inc.'s industry peers: